The combination of ginsenoside panaxatriol with paclitaxel inhibited the activation of interleukin-1 receptor-associated kinase 1(IRAK1), NF-κB and ERK1/2, leading to the inhibition of inflammatory factors, and cancer stem cell-related genes expression was downregulated and also inhibited the invasive ability of MB231-PR (paclitaxel-resistant) cells, reducing stem cell properties and resensitizing TNBC paclitaxel-resistant cells to paclitaxel by inhibiting the IRAK1/NF-κB and ERK pathways (Wang et al., 2020). Here, IRAK1 is linked to cancer.